Scientists have found a way to create cancer killing CAR-T cells inside the body. This eliminates the costly, time-consuming manufacturing process that has kept these therapies out of reach of cancer patients around the world. @j-eyquem.bsky.social

Scientists Find a Better Way to Make CAR-T Cells

YouTube video by UC San Francisco (UCSF)

youtube.com

A new study—led by Justin Eyquem from The Gladstone-UCSF Institute of Genomic Immunology —uses a dual-vector system to engineer cancer-fighting T cells in vivo, potentially simplifying and expanding access to these life-saving therapies. @j-eyquem.bsky.social

Dual-Vector System Generates CAR T Cells In Vivo

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

bit.ly

“I think this is just the beginning of a big wave of new therapies that will be truly transformational and save a lot of lives” Justin Eyquem, PhD @j-eyquem.bsky.social @ucsanfrancisco.bsky.social on recent @nature.com pub with breakthrough research on CAR T therapy www.ucsf.edu/news/2026/03...

Scientists Create Cancer-Fighting Immune Cells Right in the Body

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T has the potential to treat many more cancers.

ucsf.edu

Azalea grew out of collaborative research conducted at the Innovative Genomics Institute in Jennifer Doudna’s lab and in Justin Eyquem’s lab as part of the Gladstone-UCSF Institute of Genomic Immunology. @j-eyquem.bsky.social @innovativegenomics.bsky.social

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics launches with $82M to advance precision in vivo genome engineering, creating therapeutic cells directly inside patients....

globenewswire.com

Genomic medicine has transformed lives through ex vivo cell therapies, now it’s time to make it scalable. Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!

Ryan Cross@scienceboss.bsky.social · 11mo ago

Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...

Exciting collaboration combining multiplex epigenetic reprogramming and site-specific payload integration!

Nature Biotechnology@natbiotech.nature.com · 11mo ago

Integrated epigenetic and genetic programming of primary human T cells - @gladstoneinst.bsky.social @ucsanfrancisco.bsky.social @j-eyquem.bsky.social @marsonlab.bsky.social go.nature.com/3WOJJAJ

The Weill Cancer Hub is fostering groundbreaking @ucsanfrancisco.bsky.social - @stanford-cancer.bsky.social collaborations to develop transformative cancer therapies. I’m grateful to co-lead one of the selected teams with @mfgrp.bsky.social to advance next-generation in vivo CAR T cell therapy!

UCSF@ucsanfrancisco.bsky.social · last yr.

Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade. tiny.ucsf.edu/rZIspe

Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade. tiny.ucsf.edu/rZIspe

Gift Launches $200M Initiative for the Weill Cancer Hub West

A $100 million matching grant from the Weill Family Foundation is bringing together two leading cancer centers to launch the Weill Cancer Hub West — an innovative collaboration among some of the natio...

ucsf.edu

Excited to share our latest work, now out in @NatureBiotech ! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇 www.nature.com/articles/s41...

SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci - Nature Biotechnology

Primary T cells with multiple genetic modifications are rapidly isolated by negative selection.

nature.com

🚨New paper alert! 🚨 Our latest work in @cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇 sciencedirect.com/science/arti...

In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313

Genetic engineering of T cells in mouse models is essential for investigating immune mechanisms. We aimed to develop an approach to manipulate T cells…

sciencedirect.com

Wonderful to see the #immunology community growing here. The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added go.bsky.app/PY5tCas go.bsky.app/FmERUoD